Withdrawal of antidepressant medications may be a source of variance in dexamethasone suppression test (DST) 
The performance of the dexamethasone suppression test (DST) as a diagnostic indicator is subject to many sources of variance. These include the severity of depression (Rothschild and Schatzberg, 1982; Peselow et al.. 1983) , presence or absence of delusions (Rothschild and Schatzberg, 1982; Rudorfer et al., 1982; Schatzberg et al., 1983) , recent weight loss (Berger et al.. 1982; Edelstein et al.. 1982; Berger et al., 1983) , differences in diagnostic patterns and operational criteria from one setting to another (Targum et al., 1982a) , dose of dexamethasone (Rush et al., 1982; Brown et al., 1983) . number of postdexamethasone plasma samples analyzed (Asfeldt. 1969; Carroll et al., 198 I) , timing of such samples (Goldberg, 1980; Sachar et al., 1983) , number of DSTs performed (Carroll et al., 1981; Greden et al., 1982) , time interval between DSTs, and specificity and sensitivity of assays used to measure plasma cortisol concentrations (Demers and Derek, 1977; Meltzer, 1983; Wood et al., 1983) .
We hypothesized that recent antidepressant withdrawal is a source of variance in DST results (Dilsaver et al., 1983b; Dilsaver and Greden, 19846) . We tested this hypothesis by retrospectively measuring postdexamethasone plasma cortisol concentrations and clinical severity in patients and control subjects before, during, and after antidepressant withdrawal. After formulating the hypothesis tested in this study, we noted (Greden et al., 1983 ) that three patients monitored with weekly DSTs had suppressive (normal) responses while receiving tricyclic antidepressants but nonsuppressive (abnormal) responses soon after drug discontinuation. We conjectured that these nonsuppressive responses might be due to one of the following factors: (1) patients may have been partially treated, thus accounting for the suppressive response despite continued underlying neurobiological abnormalities that become salient only after antidepressant withdrawal; or (2) the emergence of a nonsuppressive response could be due to drug discontinuation-for example, an antidepressant (anticholinergic) withdrawal syndrome with secondary cholinergic overdrive could theoretically be a sufficient cause of DST nonsuppression (Dilsaver et al., 1983h; Dilsaver and &eden, 1984b) . Physostigmine-induced cholinergic excess can produce DST nonsuppression in normal subjects who had suppressive responses at baseline (Carroll et al., 1980; Doerr and Berger, 1983) . Further, antidepressant discontinuation can produce cholinergic overdrive (Dilsaver et al., 1983a,l9836; Dilsaver and &eden, 1983, 1984b) inclusion criteria for the I5 patients withdrawn from medication were as follows: (I) hospitalization on the Clinical Studies Unit (CSU) for Affective Disorders, a l2-bed research unit at the University of Michigan Medical Center; (2) diagnosis of major depressive disorder, endogenous subtype, based on Research Diagnostic Criteria (RDC) (Spitter et al., 1977) ; (3) withdrawal from tricyclic antidepressants shortly before or after admission to the hospital (see Results); (4) no use of benzodiazepines or sedative-hypnotics for I month preceding antidepressant discontinuation; (5) no weight loss > 20% of normal body weight (for weekly weight changes. see Results); (6) no known technical exclusion factors that might interfere with the DST (Carroll et al.. 1981) .
Inclusion
Criteria: Control Patients.
To control at least partially for the stress of hospitalization.
we identified nine control subjects who had been free of medication for a minimum of 9-I4 days before hospital admission, Because of the nature of the design, they could not be matched for all variables with the I5 drug-withdrawal subjects.
Operational
Definitions. Each patient received the routine CSU diagnostic evaluation, which includes the following: a IO-to l4-day drug-free period; two or three independent unstructured clinical interviews conducted by psychiatrists: a structured interview using the Schedule for Affective Disorders and Schizophrenia (Spitzer and Endicott, 1975) ; a diagnostic family interview conducted by a senior social worker to document longitudinal course, family history. and response to previous treatments; a review of past medical records whenever available to confirm clinical course; and a comprehensive physical examination and laboratory screening for medical illness. Consensus diagnoses then were formulated using Research Diagnostic Criteria (RDC) (Spitzer et al.. 1977) .
Clinical and demographic features are provided in Tables I and 2 . It should be noted that four subjects (#2, #5, #IO. and #14; Table I ) also were withdrawn simultaneously from antipsychotic medications (fluphenazine.
haloperidol. trifluoperazine. and chlorpromazine, respectively). We administered I mg of oral dexamethasone at 2330h and collected postdexamethasone plasma cortisol samples the following day at I600h and 2300h. Plasma samples were assayed for cortisol using a modification of Murphy's (1967) competitive protein-binding technique. The intra-assay coefficient of variation in our laboratory is 6.5%. The inter-assay coefficient of variation is 12.5% when the mean cortisol concentration is 2.5 pg/dl and 9.OYc when it is IO Fg/dl. The DST was repeated weekly.
We considered every postdexamethasone cortisol sample when we categorized subjects as nonsuppresson or suppressors. Subjects were classified as nonsuppressors if the highest postdexamethasone plasma cortisol concentration exceeded 5 pgidl. The referent value of 5 pg/dl was determined in our setting only after evaluation of patients with the disease in question (endogenous depression), patients with different disease processes (psychiatric controls), and individuals with no psychiatric disease (normal controls) (Carroll et al.. 1981) . Our referent value is based upon application of the principles of conditional probability (Galen and Gambino, 1975) to data collected on patients hospitalized on the CSU and measurements of plasma cortisol concentration using the competitive protein binding assay of Murphy (1967) . It should not be generalized indiscriminately to other settings. Each patient's primary clinician completed the l7-item Hamilton Rating Scale for Depression (HRSD) (Hamilton, 1960) weekly. Raters were always unaware of DST results. which were unavailable to clinicians until after the patient's hospital discharge.
Data Analysis.
Postdexamethasone cortisol levels were logarithmically transformed to improve normality. Paired Student's t tests were used to ascertain the level of significance of the differences in cortisol concentration during the various phases of study. When applicable, nonparametric methods were used to measure the significance of differences in the frequency of positive DSTs under the various conditions of the study. Since clinical ratings were not normally distributed even after logarithmic transformation, we compared these data with nonparametric tests. To assess possible relationships between postdexamethasone plasma cortisol concentrations and corresponding H RSD scores, we calculated correlation coefficients. One-tailed statistical analyses were used only in those instances in which our hypotheses predicted the direction of change effected by an experimental manipulation. Patients #I. #3, and #5 (Table I) had DSTs in all three phases, i.e., prewithdrawal, withdrawal. and postwithdrawal.
Patient # I5 had three DSTs, but the last two were both during the withdrawal phase. Fourteen patients, excluding #I5 (Table I) , had withdrawal and postwithdrawal (drug-free) DSTs. Based upon these distinctions, we subdivided the patient sample into two partially overlapping subsamples (#I, #3. #5. and # 15, first subsample; #I-# 14, second subsample). For each subsample, we compared cortisol concentrations from each phase with those from the other two phases using Student's paired t tests. Fig. 1 
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Abbreviations: the severity of depressive symptomatology @ > > 0. I, Wilcoxon Sign Rank Test, two-tailed).
Fourteen patients had only withdrawal and postwithdrawal DSTs. As shown in Fig.  2 , 12 had higher postdexamethasone cortisol levels during the withdrawal phase than the postwithdrawal phase (p q 0.0033, r q 3.23, u's= 13, paired t test, one-tailed). Ten of 14 (7 1%) patients were DST nonsuppressors during withdrawal, whereas 6 of 14 (42%) were nonsuppressors during the postwithdrawal phase. The Fisher's exact probability (one-tailed) wasp q 0.03. HRSD total scores did not change significantly between the prewithdrawal (mean * SD q 21 + 5), withdrawal (mean f SD = 21 f IO), and postwithdrawal (mean f SD = 21 * 10) phases (p > > 0.1, Mann-Whitney U test. two-tailed, for all statistical comparisons).
To derive an operational measure of stress-anxiety that might be associated with recent hospitalization, we summed the HRSD anxiety (ANX) and somatic anxiety (SA) subscale scores. The sum of these scores did not differ significantly between prewithdrawal(2.5 f I .5), withdrawal (3. I f 1.9). and postwithdrawal (3.4 f 2.2) phases (p > > .lO, Mann-Whitney U test, two-tailed). Fig. 3 portrays DST and clinical rating data for the total samples during each of the three phases. As recorded in Table 1 , weight did not change significantly between the prewithdrawal and postwithdrawal phase DSTs (p = 0.35. I q 0.975, df= 14.1 test on the differences, two-tailed).
The highest post-dexamethasone cortisol levels of the The four subjects with simultaneous neuroleptic and antidepressant withdrawal did not differ from the others. The difference in postdexamethasone cortisol level between the withdrawal and postwithdrawal phases for the neuroleptic (mean f SD = 3.92 f 2.97) and nonneuroleptic (mean + SD = 6.7 ? 0.35) treated subjects 0, = 0.48, t = 0.74, d' = 13) was insignificant.
We also analyzed the control group data using two time periods for comparisonthe first 14 days of hospitalization and any time thereafter ( Paired t tests were conducted between prewithdrawal and withdrawal phases for the 4 subjects who had DSTs and ratings in both phases, and between withdrawal and postwithdrawal phases for the 14 subjects who had DSTs in both phases. Clinical ratings were compared using the Wilcoxon test.
plasma cortisol concentrations following medication withdrawal might have been due to a worsening of clinical state. Our data did not support this interpretation, however. No patients worsened despite medication withdrawal, suggesting that subjects were unresponsive to treatment, were not treated for adequate periods, or that inadequate time in the drug-free state had passed for them to show significant clinical deterioration.
Different time frames might be required to detect neuroendocrine and clinical effects produced by antidepressant discontinuation; thus, these observations are not necessarily incompatible.
These pilot data suggest that the peak in hypothalamic-pituitary-adrenal (HPA) dysregulation occurs between 3 and 14 days after a tricyclic antidepressant is discontinued.
This observation is concordant with the known pharmacokinetics of commonly used antidepressants., and with the time course for development of symptoms following antidepressant withdrawal (Dilsaver and Greden. 19846 ). Conceivably, weekly administration of dexamethasone might alter HPA dexamethasone receptor sites. Findings from our semi-control group did not support this, however, nor do prior studies of serial DSTs (Greden et al., 1983; Holsboer et al., 1982) , which document moderately good state relationships between serial DSTs and clinical severity. Nevertheless, this question also warrants further prospective study. Table 1 for definitions of abbreviations.
The utility of the DST, like that of other laboratory tests, is diminished if established guidelines for application are not respected. Carroll et al. (1981) emphasized that the value of the DST is maximal when used in a clinical sample at high risk for the presence of endogenous depression, and when it is reasonably certain that the patient does not meet exclusion criteria that interfere with test interpretation. Technical exclusion criteria that invalidate the DST are still being identified. (Privitera et al., 1982; Targum et al., 1982b; Cameron et al., 1983; Kroll et al., 1983) . These retrospective pilot data suggest that recent withdrawal of antidepressants may be an exclusion criterion, and should be considered in future research investigations.
